Inventor

Orit Foord

Inventor

Foster City, CA, US

Overview

2007–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 72 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides23%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%

A61KPreparations for medical, dental or toiletry purposes22%

G01NInvestigating or analysing materials by determining their chemical or physical properties13%

C07DHeterocyclic compounds9%

C12NMicroorganisms or enzymes4%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3%

B82YSpecific uses or applications of nanostructures3%

C12YEnzymes1%

PatentTitleYear

11,033,634Light chain variable regions2021 10,836,831Anti-PTK7 antibodies and methods of use2020 10,533,051Anti SEZ6 antibodies and methods of use2020 10,508,153Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof2019 10,137,204Anti-DLL3 antibody drug conjugates for treating cancer2018 10,118,968Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof2018 10,087,258Anti-CD324 monoclonal antibodies and uses thereof2018 10,053,511Anti-claudin antibodies and methods of use2018 10,030,069High affinity human antibodies to human cytomegalovirus (CMV) gB protein2018 10,017,565Modulators and methods of use2018 9,969,798Modulators and methods of use2018 9,937,268Anti-DLL3 antibody drug conjugates and methods of use2018 9,931,420Methods of making DLL3 antibody drug conjugates2018 9,931,421Methods of delivering DLL3 antibody drug conjugates2018 9,914,784'PTK7 modulators and methods of use'2018 9,878,053'Methods of delivering DLL3 antibody drug conjugates'2018 9,867,887'Anti-DLL3 antibody drug conjugates'2018 9,861,708'Kits containing DLL3 antibody drug conjugates'2018 9,855,343'Anti-DLL3 antibody drug conjugates'2018 9,775,916'Anti-DLL3 antibody drug conjugates for treating cancer'2017 9,770,518'Anti-DLL3 antibody drug conjugates'2017 9,765,136'Modulators and methods of use'2017 9,764,042'Methods of making DLL3 antibody drug conjugates'2017 9,688,744'High affinity human antibodies to human cytomegalovirus (CMV) GB protein'2017 9,676,850'Anti SEZ6 antibodies and methods of use'2017 9,534,058'Anti-CD324 monoclonal antibodies and uses thereof'2017 9,486,537'Anti-DLL3 antibody drug conjugates'2016 9,481,727'Anti-DLL3 antibody drug conjugates'2016 9,480,757'Anti-DLL3 antibody drug conjugates'2016 9,458,231'Modulators and methods of use'2016 9,409,995'PTK7 modulators and methods of use'2016 9,358,304'Methods of making DLL3 antibody drug conjugates'2016 9,353,182'Anti-DLL3 antibodies'2016 9,352,051'Kits containing DLL3 antibody drug conjugates'2016 9,345,784'Methods of delivering DLL3 antibody drug conjugates'2016 9,334,318'Multivalent DLL3 antibodies'2016 9,320,812'Modulators and methods of use'2016 9,321,839'Antibodies immunoreactive with heregulin-coupled HER3'2016 9,321,830'Anti-RSV G protein antibodies'2016 9,173,959'Anti-DLL3 antibody drug conjugates'2015 9,155,803'Anti-DLL3 antibody drug conjugates and methods of use'2015 9,133,271'Anti-DLL3 antibody drug conjugates and methods of use'2015 9,107,961'Anti-DLL3 antibody drug conjugates for treating cancer'2015 9,096,672'Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof'2015 9,089,615'Anti-DLL3 antibodies'2015 9,089,616'Anti-DLL3 antibody drug conjugates and methods of use'2015 9,090,683'Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies'2015 9,089,617'Anti-DLL3 antibody drug conjugates'2015 9,085,624'Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof'2015 9,073,998'Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof'2015 9,062,113'Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof'2015 9,017,668'High affinity human antibodies to human cytomegalovirus (CMV) gB protein'2015 9,011,854'Anti-DLL3 antibody drug conjugates and methods of use'2015 8,986,972'Nucleic acid encoding DLL3 antibodies'2015 8,846,873'Antibodies directed to GPNMB and uses thereof'2014 8,828,382'Heparin-binding epidermal growth factor-like growth factor binding proteins'2014 8,828,388'Antibodies immunoreactive with heregulin-coupled HER3'2014 8,604,174'High affinity fully human monoclonal antibodies to interleukin-8'2013 8,362,215'Antibodies immunoreactive with heregulin-coupled HER3'2013 8,273,354'Anti-RSV G protein antibodies'2012 8,101,178'Antibodies directed to tumor necrosis factor and uses thereof'2012 7,994,302'Fully human monoclonal antibodies to IL-13'2011 7,964,193'Antibodies against interleukin-1 Î²'2011 7,736,648'Anti-RSV G protein antibodies'2010 7,736,644'Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof'2010 7,687,606'Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof'2010 7,628,986'Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof'2009 7,585,500'Fully human monoclonal antibodies to IL-13'2009 7,566,772'Antibodies against interleukin-1Î²'2009 7,482,434'Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof'2009 7,285,269'Antibodies directed to tumor necrosis factor'2007 7,202,343'Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof'2007

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2007–2019Patents assigned to AMGEN FREMONT INC (13)· patent assignee history

2007–2021Based in Foster City, CA, US· patent location history

2012–2018Patents assigned to FOORD ORIT (15)· patent assignee history

2015–2017Patents assigned to STEMCENTRX INC (20)· patent assignee history

2015–2017Patents assigned to STEM CENTRX INC (8)· patent assignee history

2016–2021Patents assigned to ABBVIE STEMCENTRX LLC (25)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
ABBVIE STEMCENTRX LLC	25	2016–2021
STEMCENTRX INC	20	2015–2017
FOORD ORITself	15	2012–2018
AMGEN FREMONT INC	13	2007–2019
STEM CENTRX INC	8	2015–2017

Locations

Location	Patents	Span
Foster City, California, US	72	2007–2021